AstraZeneca (AZN) Reports Q4 EPS of $2.12; offers guidance

AstraZeneca (NASDAQ: AZN) reported Q4 EPS of $2.12. Revenue for the quarter came in at $15.5 billion.

Guidance

AstraZeneca issues Total Revenue and Core EPS guidance4 for FY 2026 at CER, based on the average foreign exchange rates through 2025.

Total Revenue is expected to increase by a mid-to-high single-digit percentage
Core EPS is expected to increase by a low double-digit percentage

The Core Tax rate is expected to be between 18-22%

If foreign exchange rates for February 2026 to December 2026 were to remain at the average rates seen in January 2026, it is anticipated that Total Revenue in FY 2026 would benefit from a low single-digit percentage positive impact compared to the performance at CER, and Core EPS growth would be broadly similar to the growth at CER.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
• Prenetics Global (PRE) Tops Q2 EPS by 18c
• PetsForward Announces 'Paws & Purpose' Fundraising Dinner and Comedy Night at Hawkeye & Huckleberry Lounge